• 1. Novel isatin derivatives of podophyllotoxin: synthesis and cytotoxic evaluation against human leukaemia cancer cells as potent anti-MDR agents
  Lei Zhang,Fan Chen,Jing Wang,Yongzheng Chen,Zeguo Zhang,Ya Lin,Xinling Zhu RSC Adv. 2015 5 97816
• 2. Novel isatin derivatives of podophyllotoxin: synthesis and cytotoxic evaluation against human leukaemia cancer cells as potent anti-MDR agents
  Lei Zhang,Fan Chen,Jing Wang,Yongzheng Chen,Zeguo Zhang,Ya Lin,Xinling Zhu RSC Adv. 2015 5 97816
• 3. Self-assembly controlled at the level of individual functional groups
  Benjamin R. Heiner,Alexander M. Pittsford,S. Alex Kandel Chem. Commun. 2023 59 170
• 4. Zinc oxide-NP catalyzed direct indolation of in situ generated bioactive tryptanthrin
  Byanju Rai,Ratnakar Dutt Shukla,Atul Kumar Green Chem. 2018 20 822
• 5. Synthesis and antiproliferative activity of (Z)-1-glycosyl-3-(5-oxo-2-thioxoimidazolidin-4-ylidene)indolin-2-ones and (Z)-3-(2-glycosylsulfanyl-4-oxo-4,5-dihydro-thiazol-5-ylidene)indolin-2-ones
  Friedrich Erben,Dirk Michalik,Holger Feist,Dennis Kleeblatt,Martin Hein,Abdul Matin,Jamshed Iqbal,Peter Langer RSC Adv. 2014 4 10879

• Solvents and Organic Chemicals Organic Compounds Heterocyclic Compounds

Introduction to 7-fluoro-2,3-dihydro-1H-indole-2,3-dione (CAS No. 317-20-4)

7-fluoro-2,3-dihydro-1H-indole-2,3-dione is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology due to its versatile structural framework and potential biological activities. This compound, identified by the chemical abstracts service number CAS No. 317-20-4, belongs to the class of indole derivatives, which are well-known for their broad spectrum of pharmacological properties. The presence of a fluorine atom at the 7-position and the intramolecular diketone moiety contribute to its unique chemical and biological characteristics, making it a valuable scaffold for drug discovery and development.

The molecular structure of 7-fluoro-2,3-dihydro-1H-indole-2,3-dione consists of a fused indole ring system with functional groups that enhance its reactivity and binding affinity towards biological targets. The fluorine substituent is particularly noteworthy, as it is frequently employed in medicinal chemistry to modulate metabolic stability, lipophilicity, and receptor binding affinity. This feature has been extensively explored in the design of small-molecule inhibitors and activators for various therapeutic applications.

In recent years, 7-fluoro-2,3-dihydro-1H-indole-2,3-dione has been investigated for its potential role in addressing neurological disorders. The indole core is a common motif in compounds that interact with neurotransmitter systems, particularly those involving serotonin and dopamine. Preliminary studies suggest that derivatives of this compound may exhibit neuroprotective effects, making them promising candidates for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The fluorine atom's electronic properties are thought to enhance the compound's ability to cross the blood-brain barrier, a critical factor for therapeutic efficacy in central nervous system disorders.

Additionally, 7-fluoro-2,3-dihydro-1H-indole-2,3-dione has shown promise in the development of anticancer agents. The structural features of this compound allow it to interact with various enzymes and receptors involved in cancer cell proliferation and survival. Research indicates that it may inhibit key pathways such as the PI3K/Akt/mTOR signaling pathway, which is commonly dysregulated in multiple types of cancer. The diketone group provides a site for further functionalization, enabling the synthesis of analogs with enhanced potency and selectivity against specific cancer cell lines.

The synthesis of 7-fluoro-2,3-dihydro-1H-indole-2,3-dione typically involves multi-step organic reactions that build upon readily available starting materials. Common synthetic routes include cyclization reactions followed by fluorination at the 7-position. Advances in catalytic methods have improved the efficiency and scalability of these processes, making it feasible to produce larger quantities of the compound for both research and commercial purposes. The availability of high-purity 7-fluoro-2,3-dihydro-1H-indole-2,3-dione (CAS No. 317-20-4) from reputable suppliers ensures that researchers can conduct rigorous studies without compromising on quality.

In conclusion, 7-fluoro-2,3-dihydro-1H-indole-2,3-dione represents a compelling pharmacological scaffold with significant potential in therapeutic applications. Its unique structural features and demonstrated biological activities make it a focal point for ongoing research in medicinal chemistry. As our understanding of its pharmacological profile continues to evolve, this compound is likely to play an increasingly important role in the development of novel treatments for neurological disorders and cancer.

• 749240-52-6(4,7-Difluoroindoline-2,3-dione)
• 134792-45-3(6-Fluoroisatoic anhydride)
• 443-69-6(5-Fluoroisatin)
• 442910-92-1(7-fluoro-5-methyl-2,3-dihydro-1H-indole-2,3-dione)
• 107583-37-9(5,6,7-Trifluoroindoline-2,3-dione)
• 116570-41-3(5,7-Difluoroindoline-2,3-dione)
• 749240-53-7(7-fluoro-4-methyl-2,3-dihydro-1H-indole-2,3-dione)
• 774-47-0(5,6-difluoro-2,3-dihydro-1H-indole-2,3-dione)
• 324-03-8(6-fluoro-2,3-dihydro-1H-indole-2,3-dione)
• 57817-03-5(6-fluoro-7-methyl isatin)